Long-term follow-up (median 5.6 years) of 99 patients with triple-negative breast cancer in the randomised JBCRG-22 trial: with eribulin-based neoadjuvant therapy, 5-year IDFS and OS were 95% and 100% after pCR (n=20) vs 71.4% and 80.2% without pCR (n=56).
RCTn = 99
Masuda et al. Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study